Signal Genetics, Inc., a commercial stage molecular genetic diagnostic company, focuses on providing diagnostic services that assist physicians in decision making for the care of patients suffering from cancer. The company primarily offers Myeloma Prognostic Risk Signature (MyPRS) test, a microarray-based gene expression profiling assay that tests for the presence of specific groups of genes that could predict low or high level risk of early relapse in patients suffering from multiple myeloma. Signal Genetics, Inc. was founded in 2010 and is headquartered in Carlsbad, California.
http://www.priceseries.com/trade/MGEN-Miragen-Therapeutics-Inc-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2018030220180323.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments